RxDoctor Payments Data

Daryl Crenshaw, MD

Nephrology · Thomasville, GANPI 1528123965

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,258 of the $29,857 with a category attached, or 81.2%. 12 manufacturers reported payments, led by Vertex at 51.3% of the total. 2025 is the largest year on record at $27,119, more than ten times the $25 reported in 2019. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,857in general payments, 2019–2025

Across 44 payments — averaging $678.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$15K
  • AstraZeneca$9K
  • Calliditas Therapeutics US Inc.$2K
  • Travere Therapeutics, Inc.$2K
  • Vantive US Healthcare LLC$1K
  • Johnson & Johnson$375
  • plus $297 from 6 others

What the payments were for

  • Consulting fees$24,25881%
  • Speaking & faculty fees$3751%
  • Travel & lodging$4,04614%
  • Food & beverage$1,1164%
  • Education$630%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,857 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$255,558
Medicare patients
417
Services billed
1,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol174$170,361
VelphoroSucroferric Oxyhydroxide55$123,596
Thiola EcTiopronin13$65,732
MounjaroTirzepatide31$50,217
JardianceEmpagliflozin24$42,744
Sevelamer Carbonate195$40,078
LinzessLinaclotide49$37,755
LokelmaSodium Zirconium Cyclosilicate24$26,540
AuryxiaFerric Citrate25$25,982
OzempicSemaglutide19$20,530
EliquisApixaban26$16,974
ProsolParenteral Amino Acid 20% No.166$13,099
JanuviaSitagliptin Phosphate11$8,554
Calcium Acetate103$8,132
MyrbetriqMirabegron11$6,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$9,187$196,901198 claims
Fresenius USA Marketing, Inc.Velphoro$20$123,59655 claims
Akebia Therapeutics IncAuryxia$44$25,98225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.

Other nephrology in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →